IL-23: A Promising Therapeutic Target for Systemic Lupus Erythematosus

Leng, Rui‐Xue; Pan, Hai‐Feng; Chen, Gui-Mei; Wang, Chao; Qin, Wei-Zi; Chen, Lili; Tao, Jin‐Hui; Ye, Dong-Qing

doi:10.1016/j.arcmed.2010.02.011

Cited by 27 publications

(20 citation statements)

References 50 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…IL-23R is expressed on activated/memory T cells, T-cell clones, and natural killer cell lines in human. IL-23R has now been proposed as a common genetic marker for a variety of autoimmune diseases [28]. …”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Expression of IL-17, IL-23 and Their Receptors in Minor Salivary Glands of Patients with Primary Sjögren's Syndrome

Mieliauskaitė

Dumalakienė

Rugienė

et al. 2012

Clinical and Developmental Immunology

View full text Add to dashboard Cite

The main purpose of this study was to determine the expression of interleukins-17/-23 (ILs-17/-23) and receptors of interleukins-17/-23 (IL-17R, IL-23R) in minor salivary glands (MSGs) of patients with primary Sjögren's syndrome (pSS). Expression of IL-17, IL-23 and receptors of IL-17/-23 was analyzed in MSGs from 25 patients with pSS, 25 patients with probable preclinical pSS, and 25 patients with nonautoimmune sicca syndrome by immunohistochemistry. Comparison of the expression of IL-17, IL-23 and receptors of IL-17, IL-23 in MSG of patients with pSS with probable preclinical pSS, and with nonautoimmune sicca syndrome showed significant differences between three groups. However, the expression of IL-17, IL-23 and receptors of IL-17/-23 in MSG was comparable in pSS and probable preclinical pSS patients. We did not find correlation between the expression of IL-17 and IL-23 and of IL-17R and IL-23R in patients with pSS. These results demonstrate an involvement of IL-17/-23 system in the early pSS pathogenesis.

show abstract

Section: Discussionmentioning

confidence: 99%

“…Future investigations need to take these data into consideration in designing studies to examine effects of IL-23R. Furthermore, IL-23R has now been proposed as a common genetic marker for a variety of autoimmune diseases [28]. …”

Section: Discussionmentioning

confidence: 99%

Expression of IL-17, IL-23 and Their Receptors in Minor Salivary Glands of Patients with Primary Sjögren's Syndrome

Mieliauskaitė

Dumalakienė

Rugienė

et al. 2012

Clinical and Developmental Immunology

View full text Add to dashboard Cite

show abstract

“…In addition to IL-17, IL-23 was also found to be crucial for the development of various autoimmune diseases in murine models [40–42] and in humans [43] by promoting Th17 cell–mediated tissue inflammation. There is accumulating evidence indicating the importance of IL-23 in patients with SLE [44–46]. Of note, our group has shown that clinical and pathology findings of LN are mitigated in lupus prone mice with IL-23 receptor deficiency [47] or treated with an anti-IL23 antibody [48].…”

Section: Il-17 In Slementioning

confidence: 99%

T cells and IL-17 in lupus nephritis

Koga

Ichinose

Tsokos

2017

Clinical Immunology

104

View full text Add to dashboard Cite

Systemic lupus erythematosus (SLE) is a complicated autoimmune disorder characterized by autoantibodies production, immune complex formation, and immune dysregulation, resulting in damage of multiple organs including the kidney. Lupus nephritis (LN) is the most common severe manifestation of SLE involving the majority of patients. Even though there are a number of reports indicating that interleukin-17 (IL-17) and Th17 cells play important roles in the pathogenesis of LN, the precise molecular mechanisms underline the development of LN have not been totally elucidated. In this review, we briefly summarize general characteristics of T and IL-17 cells in SLE. In addition, we discuss in detail T cell signaling pathways which control IL-17 production in patients with LN and in glomerulonephritis in lupus-prone mice. A better understanding of signaling and gene regulation defects in LN will lead to the identification of novel therapeutic targets and predictive biomarkers for diagnosis and prognosis of this disease.

show abstract

“…] and evidence suggests that these cytokine might be involved in some aspects of SLE pathogenesis 92 . The results of a phase II, placebo-controlled trial of ustekinumab 93 (an antibody against IL-12 and IL-23) in 102 seropositive patients with SLE were reported in 2018.…”

Section: [H2] Targeting Il-12 and Il-23mentioning

confidence: 99%

New therapies for systemic lupus erythematosus — past imperfect, future tense

2019

View full text Add to dashboard Cite

The failure of many new, mostly biologic, drugs to meet their primary endpoints in double-blind clinical trials in patients with systemic lupus erythematosus (SLE) has caused a profound sense of disappointment among both physicians and patients. Arguably, the success of B cell depletion with rituximab in open-label clinical trials, the approval of belimumab (which blocks the B cell activating factor (BAFF)) for use in patients with lupus nephritis in the USA and in difficult-to-treat patients with SLE in the UK, and the recognition that clinical trial design can be improved has given some cause for hope. However, changes to therapies in current use and the development of new approaches are urgently needed. The results of the latest studies investigating the use of several new approaches to treat SLE are discussed in this Review, including: fully humanized anti-CD20 and anti-CD19 monoclonal antibodies; inhibition of protein tyrosine kinase BTK; CD40 ligand blockade;interfering with the presentation of antigen to autoreactive T cells using a peptide approach; a receptor decoy approach using an analogue of Fcɣ receptor IIB; dual blockade of IL-12 and IL-23; and inhibition of Janus kinases.

show abstract

IL-23: A Promising Therapeutic Target for Systemic Lupus Erythematosus

Cited by 27 publications

References 50 publications

Expression of IL-17, IL-23 and Their Receptors in Minor Salivary Glands of Patients with Primary Sjögren's Syndrome

Expression of IL-17, IL-23 and Their Receptors in Minor Salivary Glands of Patients with Primary Sjögren's Syndrome

T cells and IL-17 in lupus nephritis

New therapies for systemic lupus erythematosus — past imperfect, future tense

Contact Info

Product

Resources

About